Phase 3, ranomized, double-blind, controlled study of Cabozantinib XL 184 vs Prednisone in metastatic castration-resistant prostrate cancer patients who received prior Docetaxel and Abiraterone or MDV

Project: Research

StatusFinished
Effective start/end date1/11/1229/06/13